These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 3444847)

  • 21. Effects of membrane composition on release of model hydrophilic compound from osmotic delivery systems.
    Ozdemir N; Ozalp Y; Ozkan Y
    Acta Pol Pharm; 2000; 57(3):181-6. PubMed ID: 11143706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Swellable elementary osmotic pump (SEOP): an effective device for delivery of poorly water-soluble drugs.
    Shokri J; Ahmadi P; Rashidi P; Shahsavari M; Rajabi-Siahboomi A; Nokhodchi A
    Eur J Pharm Biopharm; 2008 Feb; 68(2):289-97. PubMed ID: 17616378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and evaluation of osmotic pump tablets of naproxen sodium.
    Ramakrishna N; Mishra B
    Pharmazie; 2001 Dec; 56(12):958-62. PubMed ID: 11802660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and evaluation of a time-specific pulsatile-release tablet of aceclofenac: a solution for morning pain in rheumatoid arthritis.
    Qureshi J; Ahuja A; Baboota S; Chutani K; Jain S; Ali J
    Methods Find Exp Clin Pharmacol; 2009; 31(1):15-23. PubMed ID: 19357794
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of drug release kinetics from ibuprofen matrix tablets using HPMC.
    Shoaib MH; Tazeen J; Merchant HA; Yousuf RI
    Pak J Pharm Sci; 2006 Apr; 19(2):119-24. PubMed ID: 16751122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extrudable core system: development of a single-layer osmotic controlled-release tablet.
    Waterman KC; MacDonald BC; Roy MC
    J Control Release; 2009 Mar; 134(3):201-6. PubMed ID: 19100796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preparation and evaluation of a novel delayed-onset sustained-release system of propranolol hydrochloride.
    Feng XM; Ren Q; Zhang WZ; Shen HF; Rong ZX; Fang C; Chen HZ
    J Pharm Pharmacol; 2008 Jul; 60(7):817-22. PubMed ID: 18549667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A model for the drug release from a polymer matrix tablet--effects of swelling and dissolution.
    Borgquist P; Körner A; Piculell L; Larsson A; Axelsson A
    J Control Release; 2006 Jul; 113(3):216-25. PubMed ID: 16797098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Time-controlled pulse-drug release from dry-coated wax matrix tablets for colon drug delivery.
    Peerapattana J; Otsuka K; Otsuka M
    Biomed Mater Eng; 2004; 14(3):293-301. PubMed ID: 15299241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new hydrogel for the extended and complete prednisolone release in the GI tract.
    Di Colo G; Baggiani A; Zambito Y; Mollica G; Geppi M; Serafini MF
    Int J Pharm; 2006 Mar; 310(1-2):154-61. PubMed ID: 16414222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transfer from immediate-release disopyramide to controlled-release disopyramide.
    DiPersio DM; Chow MS
    Angiology; 1987 Feb; 38(2 Pt 2):188-91. PubMed ID: 3103493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacologic evaluation of standard and controlled-release disopyramide.
    Siddoway LA; Barbey JT; Roden DM; Woosley RL
    Angiology; 1987 Feb; 38(2 Pt 2):184-7. PubMed ID: 3103492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Linear drug release from laminated hydroxypropyl cellulose-polyvinyl acetate films.
    Borodkin S; Tucker FE
    J Pharm Sci; 1975 Aug; 64(8):1289-94. PubMed ID: 1151700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the bioavailability of two slow release preparations of disopyramide.
    Bogaert MG; Belpaire F; De Wilde G; Lefebvre RA
    Eur J Clin Pharmacol; 1991; 40(6):629-30. PubMed ID: 1884747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Absorption studies with purines. Part 2. In vitro experiments with a diffusion apparatus (author's transl)].
    Heppt-Becker I; Schunack W
    Arzneimittelforschung; 1976 Apr; 26(4):473-6. PubMed ID: 989000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Biological availability and assessment of the antiarrhythmic activity of Disocor and Disocor Retard].
    Sadowski Z; Jasiński K; Nartowicz E; Koliński P; Ochotny R; Burduk P
    Wiad Lek; 1990 Jan 1-15; 43(1-2):65-71. PubMed ID: 2368387
    [No Abstract]   [Full Text] [Related]  

  • 37. [Cellulose acetate phthalate coating of tablets disintegrating at a predetermined intestinal position].
    Dragsted L; Boesen E; Wielandt TO; Krag E
    Ugeskr Laeger; 1979 May; 141(20):1328-30. PubMed ID: 452142
    [No Abstract]   [Full Text] [Related]  

  • 38. [Absorption studies with purines. Part 1: In vitro experiments with the Sartorius Absorption Model according to Stricker].
    Heppt-Becker I; Schunack W
    Arzneimittelforschung; 1976; 26(3):317-21. PubMed ID: 989319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Preparation and in vitro study of suppositories containing No-Spa. II. Determination of release of the active principle by membrane diffusion methods].
    Regdon G; Kovács B; Pécsiné Szebellédi I; Regdon G
    Acta Pharm Hung; 1989 Jan; 59(1):32-41. PubMed ID: 2711839
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioavailability of total and unbound disopyramide: implications for clinical use of the immediate and controlled-release dosage forms.
    Piscitelli DA; Fischer JH; Schoen MD; Hoon TJ; Bauman JL
    J Clin Pharmacol; 1994 Aug; 34(8):823-8. PubMed ID: 7962670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.